HUTCHMED(HCM) - 2022 Q2 - Quarterly Report
HUTCHMED(HCM)2022-08-01 00:00
Exhibit 99.1 HUTCHMED Reports 2022 Interim Results and Provides Business Updates Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA ® and ORPATHYS® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO® NSCLC1 patients with high MET 2levels and no prior chemotherapy Initiated six new trials thus far in 2022 with a further six starting, including with five new drug candidates FRESCO-2 Phase III, our first glob ...